Robert A Gould

US Patent:

6538112, Mar 25, 2003

Filed:

Mar 30, 2001

Appl. No.:

09/823444

Inventors:

Bohumil Bednar - North Wales PA
Daniel M. Bollag - Wyncote PA
Robert J. Gould - Green Lane PA

Assignee:

Merck Co., Inc. - Rahway NJ

International Classification:

C07K 1600

US Classification:

53038822, 53038825, 5303887, 5303871, 435 71

Abstract:

The present invention is a method for diagnosing a patient at risk to thrombocytopenia induced by administration of a GP IIb/IIIa receptor antagonist, which comprises combining i) a plasma sample of the patient; ii) detectable monoclonal antibody which recognizes induced binding sites formed on the GP IIb/IIIa receptor following association of a fibrinogen receptor antagonist with the GP IIb/IIIa receptor; and iii) GP IIb/IIIa receptor:GP IIb/III receptor antagonist complex, and determining association of the detectable monoclonal antibody with the complex in the presence of the plasma.

US Patent:

20040199934, Oct 7, 2004

Filed:

Feb 19, 2004

Appl. No.:

10/487331

Inventors:

John Hess - Lansdale PA, US
Robert Gould - Green Lane PA, US
Douglas Pettibone - Chalfont PA, US

International Classification:

A01K067/027

US Classification:

800/014000, 800/015000, 800/016000, 800/017000, 800/018000

Abstract:

Transgenic rats are generated which incorporate a primate Bbradykinin receptor transgene(s) into their genome. This Bbradykinin receptor gene is expressed in these transgenic rats, which results in binding of compounds which are selective for the primate form (such as the human form) of the receptor and not the rat form of the receptor. Therefore, the expressed transgenes within these transgenic lines mimic antagonist and agonist selectivity of the wild type primate Bbradykinin receptor. These transgenic animals are useful as a specific receptor occupancy model for modulators of the Bbradykinin receptor from the human or closely related species, as well as providing for an animal model system for assessment of the pharmacodynamic properties of such a Bbradykinin modulator(s).

US Patent:

20070011757, Jan 11, 2007

Filed:

May 16, 2006

Appl. No.:

11/434710

Inventors:

John Hess - Lansdale PA, US
Robert Gould - Green Lane PA, US
Douglas Pettibone - Chalfont PA, US

International Classification:

A01K 67/027

US Classification:

800014000, 800018000

Abstract:

Transgenic rats are generated which incorporate a primate Bbradykinin receptor transgene(s) into their genome. This Bbradykinin receptor gene is expressed in these transgenic rats, which results in binding of compounds which are selective for the primate form (such as the human form) of the receptor and not the rat form of the receptor. Therefore, the expressed transgenes within these transgenic lines mimic antagonist and agonist selectivity of the wild type primate Bbradykinin receptor. These transgenic animals are useful as a specific receptor occupancy model for modulators of the Bbradykinin receptor from the human or closely related species, as well as providing for an animal model system for assessment of the pharmacodynamic properties of such a Bbradykinin modulator(s).

US Patent:

59004142, May 4, 1999

Filed:

Aug 26, 1997

Appl. No.:

8/922836

Inventors:

Michael F. Sugrue - Blue Bell PA
George D. Hartman - Lansdale PA
Robert J. Gould - North Wales PA

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

A61K 31495
A61K 3150

US Classification:

514249

Abstract:

The compositions and methods of the invention provide a convenient means for systemically administering an integrin receptor antagonist or a pharmaceutically effective amount thereof to a patient by introducing the antagonist, in an ophthalmic formulation, to the patient's eye.

US Patent:

52179940, Jun 8, 1993

Filed:

Aug 9, 1991

Appl. No.:

7/743475

Inventors:

Melissa S. Egbertson - Ambler PA
Robert J. Gould - Green Lane PA
George D. Hartman - Lansdale PA

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

A61K 3127
A61K 3116
A61K 3119

US Classification:

514484

Abstract:

Compounds of the general formula ##STR1## and the pharmaceutically acceptable salts thereof wherein n is an integer of from 0 to 6; Y is CH. sub. 2, O, SO. sub. 2, --CONH--, --NHCO--, or ##STR2## R. sup. 1 and R. sup. 2 are independently hydrogen, C. sub. 1-8 alkyl, heterocyclyl C. sub. 0-4 alkyl, aryl C. sub. 0-4 alkyl, amino C. sub. 1-4 alkyl, C. sub. 1-4 alkylamino C. sub. 1-4 alkyl, or C. sub. 3-8 cycloalkyl wherein R. sup. 1 and R. sup. 2 may be unsubstituted or substituted with one or more groups chosen from R. sup. 3, where R. sup. 3 is hydrogen, C. sub. 1-6 alkyl, hydroxy C. sub. 0-4 alkyl, carboxy C. sub. 0-4 alkyl, C. sub. 1-4 alkyloxy C. sub.

US Patent:

56460007, Jul 8, 1997

Filed:

Sep 29, 1994

Appl. No.:

8/315034

Inventors:

Bohumil Bednar - North Wales PA
Melissa Egbertson - Ambler PA
Robert J. Gould - Green Lane PA
George D. Hartman - Landsdale PA
Jules A. Shafer - Gwynedd Valley PA

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

G01N 33567
C07D40114
C07D40106

US Classification:

435 721

Abstract:

The invention is directed to a series of novel compounds, and their pharmaceutically acceptable salts, of the formula ##STR1## wherein R is C. sub. 0-6 alkyl substituted with R. sup. 5 or a mono or polycyclic aromatic or heteroaromatic system comprised of 5 or 6-membered aromatic or heteroaromatic rings that are either unsubstituted or substituted with one or more of R. sup. 1 and R. sup. 2 ; R. sup. 1 and R. sup. 2 are independently C. sub. 1-6 alkyl, carboxyl, hydroxyl, azido, nitro, amino, C. sub. 1-6 alkylamino, C. sub. 1-6 dialkylamino, arylamino, aryl C. sub. 1-6 alkylamino, hydroxysulfonyl or arylazo; aryl is a phenyl or naphthyl ring which is unsubstituted or substituted with one or more of R. sup. 3 and R. sup. 4 ; R. sup. 3 and R. sup. 4 are independently C. sub. 1-6 alkyl, azido, nitro, amino, C. sub.

US Patent:

54571774, Oct 10, 1995

Filed:

Jun 16, 1993

Appl. No.:

8/077850

Inventors:

Daniel F. Veber - Ambler PA
Ruth F. Nutt - Green Lane PA
Dong-mei Feng - Harleysville PA
Robert J. Gould - Green Lane PA
Thomas M. Connolly - Harleysville PA

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

C07K 706
A61K 3808

US Classification:

530329

Abstract:

The radioligands are six amino acid peptides having iodinated tyrosine at amino acid position six, including Ala-pFPhe-hArg-Cha-hArg-Tyr(I)-NH. sub. 2, which mimic the activated form of the thrombin receptor protein. Thrombin receptor radioligands of the present invention are useful for screening for thrombin receptor antagonists.

US Patent:

56819269, Oct 28, 1997

Filed:

Dec 15, 1995

Appl. No.:

8/564254

Inventors:

Daniel F. Veber - Ambler PA
Ruth F. Nutt - San Diego CA
Dong-Mei Feng - Harleysville PA
Robert J. Gould - Green Lane PA
Thomas M. Connolly - Harleysville PA

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

A61K 3804
A61K 3807
A61K 3808
C07K 700

US Classification:

530329

Abstract:

Peptides having the general sequence A-B-C-D-E-F-Z wherein A is Ala, B is pFPhe, C is, for example, Arg, D is Cha, E is, for example, hArg, F is, for example, Tyr, and Z is, for example NH. sub. 2. The peptides are useful for promoting wound healing and arresting bleeding in a patient.